Adaptimmune announced the closing of its initial public offering of 11,250,000 American Depositary Shares at a price to the public of $17.00 per ADS.
Posted on 11 May 2015
Adaptimmune announced the closing of its initial public offering of 11,250,000 American Depositary Shares at a price to the public of $17.00 per ADS.
Posted on 06 May 2015
Kymab has successfully raised an additional US$50 million to complete a US$90 million Series B financing.
Posted on 05 May 2015
Adaptive Biotechnologies announced the completion of Adaptive’s Series F financing round with a $195 million investment to support several strategic growth initiatives.
Posted on 05 May 2015
Symbiomix Therapeutics announced multiple milestones, including the closing of the third and final tranche of a $41 million Series A financing and positive results from a multi-center, randomized Phase 2 trial testing a single oral dose of SYM-1219 for the treatment of bacterial vaginosis (BV).
Posted on 05 May 2015
Mirna Therapeutics announced the completion of a $41.8 million Series D financing
Posted on 05 May 2015
MyoKardia announced the successful completion of a $46 million Series B financing
Posted on 05 May 2015
Intarcia Therapeutics announced the closing of a $225 million synthetic royalty financing
Posted on 30 April 2015
CRISPR Therapeutics announced the closing of a Series A and Series B financing totaling USD 64 million
Posted on 30 April 2015
GW will issue 1,600,000 American Depositary Shares (“ADSs”), representing 19,200,000 ordinary shares of GW, at a price to the public of $112.00 per ADS on the NASDAQ Global Market
Posted on 28 April 2015
Jounce Therapeutics announced the successful completion of a $56 million oversubscribed Series B financing